Time trend analysis of long term outcome of patients with haematological malignancies admitted at dutch intensive care units

British Journal of Haematology
Vera A de VriesHEMA-ICU study group

Abstract

A few decades ago, the chances of survival for patients with a haematological malignancy needing Intensive Care Unit (ICU) support were minimal. As a consequence, ICU admission policy was cautious. We hypothesized that the long-term outcome of patients with a haematological malignancy admitted to the ICU has improved in recent years. Furthermore, our objective was to evaluate the predictive value of the Acute Physiology and Chronic Health Evaluation (APACHE) II score. A total of 1095 patients from 5 Dutch university hospitals were included from 2003 until 2015. We studied the prevalence of patients' characteristics over time. By using annual odds ratios, we analysed which patients' characteristics could have had influenced possible trends in time. A approximated mortality rate was compared with the ICU mortality rate, to study the predictive value of the APACHE II score. Overall one-year mortality was 62%. The annual decrease in one-year mortality was 7%, whereas the APACHE II score increased over time. Decreased mortality rates were particularly observed in high-risk patients (acute myeloid leukaemia, old age, low platelet count, bleeding as admission reason and need for mechanical ventilation within 24 h of ICU admission). Fu...Continue Reading

References

Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S GroegerS K Kish
May 4, 2000·The New England Journal of Medicine·UNKNOWN Acute Respiratory Distress Syndrome NetworkArthur Wheeler
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P MajorJ Seaman
Jul 5, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillaume ThiéryBenoît Schlemmer
May 6, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A GondosUNKNOWN EUNICE Survival Working Group
Feb 10, 2009·Critical Care : the Official Journal of the Critical Care Forum·Fabio Silvio TacconeJean-Louis Vincent
Jan 19, 2013·Annals of Hematology·Silvio A Namendys-SilvaAngel Herrera-Gómez
Apr 30, 2013·Critical Care : the Official Journal of the Critical Care Forum·Jack E ZimmermanWilliam A Knaus
May 10, 2013·The New England Journal of Medicine·Simon J StanworthUNKNOWN TOPPS Investigators
Jun 12, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elie AzoulayVirginie Lemiale
Jul 24, 2014·The New England Journal of Medicine·Loren GragertMartin Maiers
Oct 14, 2014·Hematology·Marijana Grgić MedićVladimir Gašparović
Jun 3, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yoshihiro InamotoPaul J Martin
Sep 1, 2015·Critical Care Medicine·Jeroen LudikhuizeUNKNOWN Cost and Outcomes of Medical Emergency Teams Study Group
Nov 29, 2015·International Journal of Epidemiology·Nick van de KlundertNicolette F de Keizer
Dec 18, 2015·European Journal of Haematology·Eduard Johannes van BeersUNKNOWN HEMA-ICU Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.